Glenmark Pharmaceuticals

GLENMARK

₹ 1,350.81

- ₹ 47.66

3.41%

Healthcare

₹ 0.00

(%)1D

Updated: 25 Apr 2025, 03:31:33 pm IST

Stock Score

Open Price

₹ 1,414.19

Prev. Close

₹ 1,398.47

₹ 1,345.25

Day Low

₹ 1,425.60

Day High

₹ 1,033.15

52 Week Low

₹ 1,812.22

52 Week High

Quick Bite

Price To Earnings Ratio -25.39	Sector PE 65.09
PB Ratio 4.87	Sector PB 8.49
EPS -53.21	Dividend Yield 0.26
Today's Volume 656.022 K	5 Day Avg. Volume 1.267 M
PEG Ratio 0.04	Market Cap. ₹ 37,880.00 Cr.

News & Events

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited is an India-based research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over the counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company's offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. The Company is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

Glenmark Pharmaceuticals Share Price

Glenmark Pharmaceuticals Ltd has a significant presence in the branded generics market in all emerging economies including India. The company entered the dermatology market with the launch of Candid cream. Glenmark's pioneering drug development focuses primarily on inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. The company's formulation business focuses on therapeutic areas, e.g. dermatology, infectious medicine, respiratory, cardiac, diabetes, gynecology, central nervous system and oncology. India is the organization's largest market region by revenue.

Glenmark Pharmaceuticals FAQs

How to Buy Glenmark Pharmaceuticals Share?

To purchase Glenmark Pharmaceuticals shares, you can open a Demat & Trading account through a broker or financial institution. Once your account is set up and funded, search for Glenmark Pharmaceuticals (ticker symbol: GLENMARK) on the trading platform provided by your broker and purchase the shares.

What's Glenmark Pharmaceuticals share price today?

The stock price of Glenmark Pharmaceuticals as of 01 May 2025 is ₹1,350.81

What is the Market Cap of Glenmark Pharmaceuticals?

Market capitalisation represents the total market value of a company's outstanding shares. As of 01 May 2025, Glenmark Pharmaceuticals (ticker symbol: GLENMARK) has a market capitalisation of approximately ₹3,78,80,00,00,000.00

What is the PE and PB ratio of Glenmark Pharmaceuticals?

Glenmark Pharmaceuticals Ltd's price-to-book ratio as of 01 May 2025 is 4.87, reflecting the market's valuation compared to its asset value. As of 01 May 2025, the trailing twelve months P/E (price-to-earnings) ratio is -25.39, indicating the market values the company at around - ₹25.39 for every ₹1 of earnings

What is the 52 Week High and Low of Glenmark Pharmaceuticals Share?

Glenmark Pharmaceuticals Ltd (GLENMARK) hit its 52-week high at ₹1,812.22, and its 52-week low at ₹1,033.15.

Begin your investment journey today

View All Global Indices